nodes	percent_of_prediction	percent_of_DWPC	metapath
Dantrolene—CYP3A4—Temozolomide—melanoma	0.22	0.576	CbGbCtD
Dantrolene—CYP3A4—Vemurafenib—melanoma	0.121	0.316	CbGbCtD
Dantrolene—CYP3A4—Docetaxel—melanoma	0.0414	0.108	CbGbCtD
Dantrolene—RYR3—MFAP5-mediated ovarian cancer cell motility and invasiveness—ITGAV—melanoma	0.0221	0.121	CbGpPWpGaD
Dantrolene—RYR3—MFAP5-mediated ovarian cancer cell motility and invasiveness—ITGB3—melanoma	0.0174	0.0955	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—PLCB4—melanoma	0.0128	0.0701	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—CAPN1—melanoma	0.012	0.0659	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—APAF1—melanoma	0.00775	0.0425	CbGpPWpGaD
Dantrolene—RYR3—MFAP5-mediated ovarian cancer cell motility and invasiveness—MAPK1—melanoma	0.00735	0.0403	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—GRIN2A—melanoma	0.00735	0.0403	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—GNAQ—melanoma	0.00531	0.0291	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCB5—melanoma	0.00513	0.0281	CbGpPWpGaD
Dantrolene—Speech disorder—Carmustine—melanoma	0.00406	0.00934	CcSEcCtD
Dantrolene—Extravasation—Carmustine—melanoma	0.004	0.00921	CcSEcCtD
Dantrolene—Speech disorder—Temozolomide—melanoma	0.00392	0.00902	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCB5—melanoma	0.00379	0.0207	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—FAS—melanoma	0.00365	0.02	CbGpPWpGaD
Dantrolene—Eruption—Docetaxel—melanoma	0.00365	0.00839	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ARL2—melanoma	0.00356	0.0195	CbGpPWpGaD
Dantrolene—Aplastic anaemia—Dactinomycin—melanoma	0.0035	0.00806	CcSEcCtD
Dantrolene—Injection site reaction—Carmustine—melanoma	0.00347	0.00798	CcSEcCtD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—GNA11—melanoma	0.00344	0.0188	CbGpPWpGaD
Dantrolene—Respiratory failure—Temozolomide—melanoma	0.00344	0.0079	CcSEcCtD
Dantrolene—Urinary incontinence—Carmustine—melanoma	0.00337	0.00776	CcSEcCtD
Dantrolene—Phlebitis—Bleomycin—melanoma	0.00337	0.00775	CcSEcCtD
Dantrolene—Intestinal obstruction—Docetaxel—melanoma	0.00329	0.00757	CcSEcCtD
Dantrolene—Urinary incontinence—Temozolomide—melanoma	0.00326	0.0075	CcSEcCtD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—GNAQ—melanoma	0.0032	0.0175	CbGpPWpGaD
Dantrolene—Aplastic anaemia—Temozolomide—melanoma	0.00317	0.00729	CcSEcCtD
Dantrolene—Phlebitis—Dactinomycin—melanoma	0.00314	0.00723	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—GNAQ—melanoma	0.0031	0.017	CbGpPWpGaD
Dantrolene—Hepatic failure—Dactinomycin—melanoma	0.00301	0.00693	CcSEcCtD
Dantrolene—Chills—Vemurafenib—melanoma	0.00298	0.00684	CcSEcCtD
Dantrolene—Phlebitis—Carmustine—melanoma	0.00294	0.00677	CcSEcCtD
Dantrolene—Pleural effusion—Docetaxel—melanoma	0.00293	0.00674	CcSEcCtD
Dantrolene—Thrombophlebitis—Carmustine—melanoma	0.00293	0.00674	CcSEcCtD
Dantrolene—Hepatotoxicity—Docetaxel—melanoma	0.00291	0.00668	CcSEcCtD
Dantrolene—Erythema—Vemurafenib—melanoma	0.00289	0.00664	CcSEcCtD
Dantrolene—Swelling—Carmustine—melanoma	0.00287	0.00661	CcSEcCtD
Dantrolene—Necrosis—Docetaxel—melanoma	0.00286	0.00658	CcSEcCtD
Dantrolene—Thrombophlebitis—Temozolomide—melanoma	0.00283	0.00651	CcSEcCtD
Dantrolene—Dysgeusia—Vemurafenib—melanoma	0.00283	0.0065	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—CASP8—melanoma	0.00282	0.0154	CbGpPWpGaD
Dantrolene—Back pain—Vemurafenib—melanoma	0.00279	0.00642	CcSEcCtD
Dantrolene—Hepatic failure—Temozolomide—melanoma	0.00273	0.00627	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC15A2—melanoma	0.0027	0.0148	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ARL2—melanoma	0.00262	0.0144	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC17A5—melanoma	0.0026	0.0142	CbGpPWpGaD
Dantrolene—Extravasation—Docetaxel—melanoma	0.00257	0.00592	CcSEcCtD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—GNA11—melanoma	0.00254	0.0139	CbGpPWpGaD
Dantrolene—Gastrointestinal haemorrhage—Carmustine—melanoma	0.00253	0.00583	CcSEcCtD
Dantrolene—Diplopia—Carmustine—melanoma	0.00253	0.00583	CcSEcCtD
Dantrolene—Myalgia—Vemurafenib—melanoma	0.00246	0.00565	CcSEcCtD
Dantrolene—Diplopia—Temozolomide—melanoma	0.00245	0.00563	CcSEcCtD
Dantrolene—Lacrimation increased—Docetaxel—melanoma	0.00244	0.0056	CcSEcCtD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—GNAQ—melanoma	0.00236	0.0129	CbGpPWpGaD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC6A11—melanoma	0.00236	0.0129	CbGpPWpGaD
Dantrolene—Anaphylactic shock—Vemurafenib—melanoma	0.00236	0.00542	CcSEcCtD
Dantrolene—Dysphagia—Dactinomycin—melanoma	0.00234	0.00538	CcSEcCtD
Dantrolene—RYR3—Calcium Regulation in the Cardiac Cell—PRKCA—melanoma	0.00232	0.0127	CbGpPWpGaD
Dantrolene—Respiratory failure—Docetaxel—melanoma	0.00229	0.00526	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—GNAQ—melanoma	0.00228	0.0125	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—PRKCA—melanoma	0.00225	0.0123	CbGpPWpGaD
Dantrolene—Muscular weakness—Carmustine—melanoma	0.00224	0.00514	CcSEcCtD
Dantrolene—Injection site reaction—Docetaxel—melanoma	0.00223	0.00513	CcSEcCtD
Dantrolene—Dysphagia—Carmustine—melanoma	0.00219	0.00504	CcSEcCtD
Dantrolene—Muscular weakness—Temozolomide—melanoma	0.00216	0.00497	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00215	0.00494	CcSEcCtD
Dantrolene—Haematuria—Bleomycin—melanoma	0.00213	0.00491	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—CASP3—melanoma	0.00213	0.0117	CbGpPWpGaD
Dantrolene—Dysphagia—Temozolomide—melanoma	0.00212	0.00487	CcSEcCtD
Dantrolene—Decreased appetite—Vemurafenib—melanoma	0.00205	0.00471	CcSEcCtD
Dantrolene—Fatigue—Vemurafenib—melanoma	0.00203	0.00467	CcSEcCtD
Dantrolene—Haemoglobin—Bleomycin—melanoma	0.00202	0.00464	CcSEcCtD
Dantrolene—Constipation—Vemurafenib—melanoma	0.00201	0.00463	CcSEcCtD
Dantrolene—Haemorrhage—Bleomycin—melanoma	0.00201	0.00462	CcSEcCtD
Dantrolene—Lightheadedness—Docetaxel—melanoma	0.00201	0.00462	CcSEcCtD
Dantrolene—Pulmonary oedema—Docetaxel—melanoma	0.002	0.00459	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC15A2—melanoma	0.00199	0.0109	CbGpPWpGaD
Dantrolene—Pollakiuria—Temozolomide—melanoma	0.00196	0.0045	CcSEcCtD
Dantrolene—Depression—Carmustine—melanoma	0.00195	0.00448	CcSEcCtD
Dantrolene—Renal failure—Carmustine—melanoma	0.00192	0.00442	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC17A5—melanoma	0.00191	0.0105	CbGpPWpGaD
Dantrolene—Phlebitis—Docetaxel—melanoma	0.00189	0.00435	CcSEcCtD
Dantrolene—Depression—Temozolomide—melanoma	0.00188	0.00433	CcSEcCtD
Dantrolene—Thrombophlebitis—Docetaxel—melanoma	0.00188	0.00433	CcSEcCtD
Dantrolene—Hepatitis—Dactinomycin—melanoma	0.00187	0.00431	CcSEcCtD
Dantrolene—Flushing—Bleomycin—melanoma	0.00186	0.00429	CcSEcCtD
Dantrolene—Body temperature increased—Vemurafenib—melanoma	0.00186	0.00428	CcSEcCtD
Dantrolene—Swelling—Docetaxel—melanoma	0.00185	0.00425	CcSEcCtD
Dantrolene—Hepatic failure—Docetaxel—melanoma	0.00181	0.00417	CcSEcCtD
Dantrolene—Chills—Bleomycin—melanoma	0.0018	0.00415	CcSEcCtD
Dantrolene—Haemoglobin—Carmustine—melanoma	0.00176	0.00405	CcSEcCtD
Dantrolene—Haemorrhage—Carmustine—melanoma	0.00175	0.00403	CcSEcCtD
Dantrolene—Erythema—Bleomycin—melanoma	0.00175	0.00402	CcSEcCtD
Dantrolene—Flushing—Dactinomycin—melanoma	0.00174	0.004	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC6A11—melanoma	0.00174	0.00952	CbGpPWpGaD
Dantrolene—Hypersensitivity—Vemurafenib—melanoma	0.00174	0.00399	CcSEcCtD
Dantrolene—Visual disturbance—Docetaxel—melanoma	0.00172	0.00395	CcSEcCtD
Dantrolene—RYR1—Calcium Regulation in the Cardiac Cell—PRKCA—melanoma	0.00171	0.00938	CbGpPWpGaD
Dantrolene—RYR3—Alzheimers Disease—MAPK3—melanoma	0.00171	0.00937	CbGpPWpGaD
Dantrolene—Haemoglobin—Temozolomide—melanoma	0.0017	0.00392	CcSEcCtD
Dantrolene—Hepatitis—Temozolomide—melanoma	0.00169	0.0039	CcSEcCtD
Dantrolene—Haemorrhage—Temozolomide—melanoma	0.00169	0.0039	CcSEcCtD
Dantrolene—Asthenia—Vemurafenib—melanoma	0.00169	0.00389	CcSEcCtD
Dantrolene—Visual impairment—Carmustine—melanoma	0.00169	0.00389	CcSEcCtD
Dantrolene—Chills—Dactinomycin—melanoma	0.00168	0.00387	CcSEcCtD
Dantrolene—Cardiac failure—Docetaxel—melanoma	0.00167	0.00384	CcSEcCtD
Dantrolene—Pruritus—Vemurafenib—melanoma	0.00167	0.00383	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—PRKCA—melanoma	0.00166	0.00909	CbGpPWpGaD
Dantrolene—Visual impairment—Temozolomide—melanoma	0.00163	0.00376	CcSEcCtD
Dantrolene—Erythema—Dactinomycin—melanoma	0.00163	0.00375	CcSEcCtD
Dantrolene—Pain in extremity—Docetaxel—melanoma	0.00163	0.00375	CcSEcCtD
Dantrolene—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.00163	0.00375	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—MAPK1—melanoma	0.00163	0.00892	CbGpPWpGaD
Dantrolene—Flushing—Carmustine—melanoma	0.00163	0.00374	CcSEcCtD
Dantrolene—Ill-defined disorder—Bleomycin—melanoma	0.00162	0.00373	CcSEcCtD
Dantrolene—Anaemia—Bleomycin—melanoma	0.00162	0.00372	CcSEcCtD
Dantrolene—Diarrhoea—Vemurafenib—melanoma	0.00161	0.00371	CcSEcCtD
Dantrolene—Malaise—Bleomycin—melanoma	0.00158	0.00363	CcSEcCtD
Dantrolene—Flushing—Temozolomide—melanoma	0.00157	0.00362	CcSEcCtD
Dantrolene—Leukopenia—Bleomycin—melanoma	0.00157	0.0036	CcSEcCtD
Dantrolene—Dizziness—Vemurafenib—melanoma	0.00156	0.00358	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—TNF—melanoma	0.00155	0.00849	CbGpPWpGaD
Dantrolene—Erythema—Carmustine—melanoma	0.00153	0.00351	CcSEcCtD
Dantrolene—Chills—Temozolomide—melanoma	0.00152	0.0035	CcSEcCtD
Dantrolene—Ill-defined disorder—Dactinomycin—melanoma	0.00151	0.00348	CcSEcCtD
Dantrolene—Anaemia—Dactinomycin—melanoma	0.00151	0.00347	CcSEcCtD
Dantrolene—Vomiting—Vemurafenib—melanoma	0.0015	0.00345	CcSEcCtD
Dantrolene—CYP3A4—Liver X Receptor Pathway—FASN—melanoma	0.00149	0.00818	CbGpPWpGaD
Dantrolene—Myalgia—Bleomycin—melanoma	0.00149	0.00342	CcSEcCtD
Dantrolene—Rash—Vemurafenib—melanoma	0.00149	0.00342	CcSEcCtD
Dantrolene—Dermatitis—Vemurafenib—melanoma	0.00148	0.00341	CcSEcCtD
Dantrolene—CYP3A4—Benzo(a)pyrene metabolism—CYP1B1—melanoma	0.00148	0.0081	CbGpPWpGaD
Dantrolene—Back pain—Carmustine—melanoma	0.00148	0.0034	CcSEcCtD
Dantrolene—Headache—Vemurafenib—melanoma	0.00148	0.00339	CcSEcCtD
Dantrolene—Erythema—Temozolomide—melanoma	0.00148	0.00339	CcSEcCtD
Dantrolene—Discomfort—Bleomycin—melanoma	0.00147	0.00338	CcSEcCtD
Dantrolene—Malaise—Dactinomycin—melanoma	0.00147	0.00338	CcSEcCtD
Dantrolene—Leukopenia—Dactinomycin—melanoma	0.00146	0.00336	CcSEcCtD
Dantrolene—Dysgeusia—Temozolomide—melanoma	0.00144	0.00332	CcSEcCtD
Dantrolene—Confusional state—Bleomycin—melanoma	0.00144	0.00331	CcSEcCtD
Dantrolene—Vision blurred—Carmustine—melanoma	0.00144	0.00331	CcSEcCtD
Dantrolene—Anaphylactic shock—Bleomycin—melanoma	0.00143	0.00328	CcSEcCtD
Dantrolene—Back pain—Temozolomide—melanoma	0.00143	0.00328	CcSEcCtD
Dantrolene—Anaemia—Carmustine—melanoma	0.00141	0.00325	CcSEcCtD
Dantrolene—Dysphagia—Docetaxel—melanoma	0.00141	0.00324	CcSEcCtD
Dantrolene—Nausea—Vemurafenib—melanoma	0.0014	0.00322	CcSEcCtD
Dantrolene—Thrombocytopenia—Bleomycin—melanoma	0.0014	0.00321	CcSEcCtD
Dantrolene—Vision blurred—Temozolomide—melanoma	0.00139	0.0032	CcSEcCtD
Dantrolene—Myalgia—Dactinomycin—melanoma	0.00139	0.00319	CcSEcCtD
Dantrolene—Discomfort—Dactinomycin—melanoma	0.00137	0.00316	CcSEcCtD
Dantrolene—Ill-defined disorder—Temozolomide—melanoma	0.00137	0.00315	CcSEcCtD
Dantrolene—RYR3—Alzheimers Disease—TP53—melanoma	0.00137	0.00748	CbGpPWpGaD
Dantrolene—Leukopenia—Carmustine—melanoma	0.00137	0.00314	CcSEcCtD
Dantrolene—Anaemia—Temozolomide—melanoma	0.00136	0.00314	CcSEcCtD
Dantrolene—Anorexia—Bleomycin—melanoma	0.00136	0.00313	CcSEcCtD
Dantrolene—CYP3A4—Codeine and Morphine Metabolism—ABCB1—melanoma	0.00134	0.00733	CbGpPWpGaD
Dantrolene—Malaise—Temozolomide—melanoma	0.00133	0.00306	CcSEcCtD
Dantrolene—Convulsion—Carmustine—melanoma	0.00132	0.00304	CcSEcCtD
Dantrolene—Leukopenia—Temozolomide—melanoma	0.00132	0.00304	CcSEcCtD
Dantrolene—Hypertension—Carmustine—melanoma	0.00132	0.00303	CcSEcCtD
Dantrolene—Thrombocytopenia—Dactinomycin—melanoma	0.0013	0.003	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Bleomycin—melanoma	0.0013	0.00299	CcSEcCtD
Dantrolene—Myalgia—Carmustine—melanoma	0.0013	0.00299	CcSEcCtD
Dantrolene—Convulsion—Temozolomide—melanoma	0.00128	0.00294	CcSEcCtD
Dantrolene—Hypertension—Temozolomide—melanoma	0.00127	0.00293	CcSEcCtD
Dantrolene—Anorexia—Dactinomycin—melanoma	0.00127	0.00292	CcSEcCtD
Dantrolene—Confusional state—Carmustine—melanoma	0.00126	0.00289	CcSEcCtD
Dantrolene—Myalgia—Temozolomide—melanoma	0.00126	0.00289	CcSEcCtD
Dantrolene—Discomfort—Temozolomide—melanoma	0.00124	0.00285	CcSEcCtD
Dantrolene—Decreased appetite—Bleomycin—melanoma	0.00124	0.00285	CcSEcCtD
Dantrolene—Renal failure—Docetaxel—melanoma	0.00123	0.00284	CcSEcCtD
Dantrolene—Dry mouth—Temozolomide—melanoma	0.00123	0.00283	CcSEcCtD
Dantrolene—Pain—Bleomycin—melanoma	0.00122	0.00281	CcSEcCtD
Dantrolene—Thrombocytopenia—Carmustine—melanoma	0.00122	0.00281	CcSEcCtD
Dantrolene—Tachycardia—Carmustine—melanoma	0.00122	0.0028	CcSEcCtD
Dantrolene—Confusional state—Temozolomide—melanoma	0.00121	0.00279	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00121	0.00279	CcSEcCtD
Dantrolene—Anaphylactic shock—Temozolomide—melanoma	0.0012	0.00277	CcSEcCtD
Dantrolene—Anorexia—Carmustine—melanoma	0.00119	0.00273	CcSEcCtD
Dantrolene—Thrombocytopenia—Temozolomide—melanoma	0.00118	0.00271	CcSEcCtD
Dantrolene—Feeling abnormal—Bleomycin—melanoma	0.00118	0.00271	CcSEcCtD
Dantrolene—Hyperhidrosis—Temozolomide—melanoma	0.00116	0.00268	CcSEcCtD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—NFKB1—melanoma	0.00116	0.00637	CbGpPWpGaD
Dantrolene—Decreased appetite—Dactinomycin—melanoma	0.00116	0.00266	CcSEcCtD
Dantrolene—Fatigue—Dactinomycin—melanoma	0.00115	0.00264	CcSEcCtD
Dantrolene—Anorexia—Temozolomide—melanoma	0.00115	0.00264	CcSEcCtD
Dantrolene—Pain—Dactinomycin—melanoma	0.00114	0.00262	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Carmustine—melanoma	0.00114	0.00261	CcSEcCtD
Dantrolene—Urticaria—Bleomycin—melanoma	0.00113	0.00261	CcSEcCtD
Dantrolene—Haemoglobin—Docetaxel—melanoma	0.00113	0.00261	CcSEcCtD
Dantrolene—Body temperature increased—Bleomycin—melanoma	0.00113	0.0026	CcSEcCtD
Dantrolene—Haemorrhage—Docetaxel—melanoma	0.00113	0.00259	CcSEcCtD
Dantrolene—Hepatitis—Docetaxel—melanoma	0.00113	0.00259	CcSEcCtD
Dantrolene—Insomnia—Carmustine—melanoma	0.00113	0.00259	CcSEcCtD
Dantrolene—Somnolence—Carmustine—melanoma	0.00111	0.00255	CcSEcCtD
Dantrolene—Feeling abnormal—Dactinomycin—melanoma	0.0011	0.00252	CcSEcCtD
Dantrolene—Musculoskeletal discomfort—Temozolomide—melanoma	0.0011	0.00252	CcSEcCtD
Dantrolene—Insomnia—Temozolomide—melanoma	0.00109	0.0025	CcSEcCtD
Dantrolene—Gastrointestinal pain—Dactinomycin—melanoma	0.00109	0.0025	CcSEcCtD
Dantrolene—Visual impairment—Docetaxel—melanoma	0.00109	0.0025	CcSEcCtD
Dantrolene—Decreased appetite—Carmustine—melanoma	0.00108	0.00249	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—SLC5A5—melanoma	0.00108	0.0059	CbGpPWpGaD
Dantrolene—Somnolence—Temozolomide—melanoma	0.00107	0.00246	CcSEcCtD
Dantrolene—Constipation—Carmustine—melanoma	0.00107	0.00245	CcSEcCtD
Dantrolene—Pain—Carmustine—melanoma	0.00107	0.00245	CcSEcCtD
Dantrolene—Dyspepsia—Temozolomide—melanoma	0.00106	0.00244	CcSEcCtD
Dantrolene—Abdominal pain—Dactinomycin—melanoma	0.00105	0.00242	CcSEcCtD
Dantrolene—Body temperature increased—Dactinomycin—melanoma	0.00105	0.00242	CcSEcCtD
Dantrolene—Hypersensitivity—Bleomycin—melanoma	0.00105	0.00242	CcSEcCtD
Dantrolene—Decreased appetite—Temozolomide—melanoma	0.00105	0.00241	CcSEcCtD
Dantrolene—Flushing—Docetaxel—melanoma	0.00105	0.00241	CcSEcCtD
Dantrolene—Fatigue—Temozolomide—melanoma	0.00104	0.00239	CcSEcCtD
Dantrolene—Pain—Temozolomide—melanoma	0.00103	0.00237	CcSEcCtD
Dantrolene—Constipation—Temozolomide—melanoma	0.00103	0.00237	CcSEcCtD
Dantrolene—Feeling abnormal—Carmustine—melanoma	0.00103	0.00236	CcSEcCtD
Dantrolene—Asthenia—Bleomycin—melanoma	0.00102	0.00236	CcSEcCtD
Dantrolene—Gastrointestinal pain—Carmustine—melanoma	0.00102	0.00234	CcSEcCtD
Dantrolene—Chills—Docetaxel—melanoma	0.00101	0.00233	CcSEcCtD
Dantrolene—Pruritus—Bleomycin—melanoma	0.00101	0.00232	CcSEcCtD
Dantrolene—Feeling abnormal—Temozolomide—melanoma	0.000992	0.00228	CcSEcCtD
Dantrolene—Abdominal pain—Carmustine—melanoma	0.000985	0.00227	CcSEcCtD
Dantrolene—Body temperature increased—Carmustine—melanoma	0.000985	0.00227	CcSEcCtD
Dantrolene—Gastrointestinal pain—Temozolomide—melanoma	0.000985	0.00226	CcSEcCtD
Dantrolene—Erythema—Docetaxel—melanoma	0.000981	0.00226	CcSEcCtD
Dantrolene—Hypersensitivity—Dactinomycin—melanoma	0.000981	0.00226	CcSEcCtD
Dantrolene—Dysgeusia—Docetaxel—melanoma	0.000961	0.00221	CcSEcCtD
Dantrolene—Urticaria—Temozolomide—melanoma	0.000956	0.0022	CcSEcCtD
Dantrolene—Asthenia—Dactinomycin—melanoma	0.000955	0.0022	CcSEcCtD
Dantrolene—Abdominal pain—Temozolomide—melanoma	0.000952	0.00219	CcSEcCtD
Dantrolene—Body temperature increased—Temozolomide—melanoma	0.000952	0.00219	CcSEcCtD
Dantrolene—Back pain—Docetaxel—melanoma	0.000949	0.00218	CcSEcCtD
Dantrolene—Hypersensitivity—Carmustine—melanoma	0.000918	0.00211	CcSEcCtD
Dantrolene—Diarrhoea—Dactinomycin—melanoma	0.000911	0.00209	CcSEcCtD
Dantrolene—Vomiting—Bleomycin—melanoma	0.000908	0.00209	CcSEcCtD
Dantrolene—Anaemia—Docetaxel—melanoma	0.000907	0.00209	CcSEcCtD
Dantrolene—Rash—Bleomycin—melanoma	0.0009	0.00207	CcSEcCtD
Dantrolene—Dermatitis—Bleomycin—melanoma	0.000899	0.00207	CcSEcCtD
Dantrolene—Asthenia—Carmustine—melanoma	0.000894	0.00206	CcSEcCtD
Dantrolene—Hypersensitivity—Temozolomide—melanoma	0.000887	0.00204	CcSEcCtD
Dantrolene—Leukopenia—Docetaxel—melanoma	0.000878	0.00202	CcSEcCtD
Dantrolene—Asthenia—Temozolomide—melanoma	0.000864	0.00199	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—NFKB1—melanoma	0.000857	0.00469	CbGpPWpGaD
Dantrolene—Diarrhoea—Carmustine—melanoma	0.000852	0.00196	CcSEcCtD
Dantrolene—Pruritus—Temozolomide—melanoma	0.000852	0.00196	CcSEcCtD
Dantrolene—Convulsion—Docetaxel—melanoma	0.00085	0.00196	CcSEcCtD
Dantrolene—CYP3A4—Estrogen metabolism—CYP1B1—melanoma	0.00085	0.00465	CbGpPWpGaD
Dantrolene—Nausea—Bleomycin—melanoma	0.000848	0.00195	CcSEcCtD
Dantrolene—Hypertension—Docetaxel—melanoma	0.000847	0.00195	CcSEcCtD
Dantrolene—Vomiting—Dactinomycin—melanoma	0.000846	0.00195	CcSEcCtD
Dantrolene—Rash—Dactinomycin—melanoma	0.000839	0.00193	CcSEcCtD
Dantrolene—Myalgia—Docetaxel—melanoma	0.000835	0.00192	CcSEcCtD
Dantrolene—Dizziness—Carmustine—melanoma	0.000824	0.00189	CcSEcCtD
Dantrolene—Diarrhoea—Temozolomide—melanoma	0.000824	0.00189	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ABCB1—melanoma	0.000822	0.0045	CbGpPWpGaD
Dantrolene—Dry mouth—Docetaxel—melanoma	0.000817	0.00188	CcSEcCtD
Dantrolene—Confusional state—Docetaxel—melanoma	0.000807	0.00186	CcSEcCtD
Dantrolene—Anaphylactic shock—Docetaxel—melanoma	0.000801	0.00184	CcSEcCtD
Dantrolene—Dizziness—Temozolomide—melanoma	0.000796	0.00183	CcSEcCtD
Dantrolene—RYR1—Transmembrane transport of small molecules—SLC5A5—melanoma	0.000795	0.00435	CbGpPWpGaD
Dantrolene—Vomiting—Carmustine—melanoma	0.000792	0.00182	CcSEcCtD
Dantrolene—Nausea—Dactinomycin—melanoma	0.000791	0.00182	CcSEcCtD
Dantrolene—Rash—Carmustine—melanoma	0.000786	0.00181	CcSEcCtD
Dantrolene—Dermatitis—Carmustine—melanoma	0.000785	0.00181	CcSEcCtD
Dantrolene—Thrombocytopenia—Docetaxel—melanoma	0.000784	0.0018	CcSEcCtD
Dantrolene—Tachycardia—Docetaxel—melanoma	0.000781	0.0018	CcSEcCtD
Dantrolene—Headache—Carmustine—melanoma	0.000781	0.0018	CcSEcCtD
Dantrolene—Vomiting—Temozolomide—melanoma	0.000766	0.00176	CcSEcCtD
Dantrolene—Anorexia—Docetaxel—melanoma	0.000763	0.00176	CcSEcCtD
Dantrolene—Rash—Temozolomide—melanoma	0.000759	0.00175	CcSEcCtD
Dantrolene—Dermatitis—Temozolomide—melanoma	0.000758	0.00174	CcSEcCtD
Dantrolene—Headache—Temozolomide—melanoma	0.000754	0.00173	CcSEcCtD
Dantrolene—CYP3A4—Tamoxifen metabolism—CYP1B1—melanoma	0.000751	0.00411	CbGpPWpGaD
Dantrolene—Nausea—Carmustine—melanoma	0.00074	0.0017	CcSEcCtD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—melanoma	0.000732	0.00401	CbGpPWpGaD
Dantrolene—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—melanoma	0.000731	0.004	CbGpPWpGaD
Dantrolene—RYR3—Myometrial Relaxation and Contraction Pathways—IL6—melanoma	0.00073	0.004	CbGpPWpGaD
Dantrolene—Musculoskeletal discomfort—Docetaxel—melanoma	0.000729	0.00168	CcSEcCtD
Dantrolene—Insomnia—Docetaxel—melanoma	0.000724	0.00167	CcSEcCtD
Dantrolene—Nausea—Temozolomide—melanoma	0.000715	0.00164	CcSEcCtD
Dantrolene—Somnolence—Docetaxel—melanoma	0.000712	0.00164	CcSEcCtD
Dantrolene—Dyspepsia—Docetaxel—melanoma	0.000705	0.00162	CcSEcCtD
Dantrolene—Decreased appetite—Docetaxel—melanoma	0.000696	0.0016	CcSEcCtD
Dantrolene—Fatigue—Docetaxel—melanoma	0.00069	0.00159	CcSEcCtD
Dantrolene—Pain—Docetaxel—melanoma	0.000685	0.00157	CcSEcCtD
Dantrolene—Constipation—Docetaxel—melanoma	0.000685	0.00157	CcSEcCtD
Dantrolene—Feeling abnormal—Docetaxel—melanoma	0.00066	0.00152	CcSEcCtD
Dantrolene—Gastrointestinal pain—Docetaxel—melanoma	0.000655	0.00151	CcSEcCtD
Dantrolene—Body temperature increased—Docetaxel—melanoma	0.000633	0.00146	CcSEcCtD
Dantrolene—Abdominal pain—Docetaxel—melanoma	0.000633	0.00146	CcSEcCtD
Dantrolene—CYP3A4—Irinotecan Pathway—APC—melanoma	0.000617	0.00338	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ABCB1—melanoma	0.000606	0.00332	CbGpPWpGaD
Dantrolene—Hypersensitivity—Docetaxel—melanoma	0.00059	0.00136	CcSEcCtD
Dantrolene—Asthenia—Docetaxel—melanoma	0.000574	0.00132	CcSEcCtD
Dantrolene—Pruritus—Docetaxel—melanoma	0.000566	0.0013	CcSEcCtD
Dantrolene—Diarrhoea—Docetaxel—melanoma	0.000548	0.00126	CcSEcCtD
Dantrolene—RYR1—Myometrial Relaxation and Contraction Pathways—IL6—melanoma	0.000538	0.00295	CbGpPWpGaD
Dantrolene—Dizziness—Docetaxel—melanoma	0.000529	0.00122	CcSEcCtD
Dantrolene—RYR3—Transmembrane transport of small molecules—ALB—melanoma	0.000514	0.00282	CbGpPWpGaD
Dantrolene—Vomiting—Docetaxel—melanoma	0.000509	0.00117	CcSEcCtD
Dantrolene—Rash—Docetaxel—melanoma	0.000505	0.00116	CcSEcCtD
Dantrolene—Dermatitis—Docetaxel—melanoma	0.000504	0.00116	CcSEcCtD
Dantrolene—Headache—Docetaxel—melanoma	0.000502	0.00115	CcSEcCtD
Dantrolene—CYP3A4—Biological oxidations—UGT2B10—melanoma	0.000498	0.00273	CbGpPWpGaD
Dantrolene—Nausea—Docetaxel—melanoma	0.000476	0.00109	CcSEcCtD
Dantrolene—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—melanoma	0.000442	0.00242	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—melanoma	0.000421	0.0023	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—melanoma	0.00042	0.0023	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—CYP1B1—melanoma	0.000401	0.0022	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP17A1—melanoma	0.000385	0.00211	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP17A1—melanoma	0.00038	0.00208	CbGpPWpGaD
Dantrolene—RYR1—Transmembrane transport of small molecules—ALB—melanoma	0.000379	0.00208	CbGpPWpGaD
Dantrolene—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—melanoma	0.000324	0.00178	CbGpPWpGaD
Dantrolene—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—melanoma	0.00032	0.00175	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—AKR1B10—melanoma	0.000316	0.00173	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	0.000312	0.00171	CbGpPWpGaD
Dantrolene—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—melanoma	0.000293	0.0016	CbGpPWpGaD
Dantrolene—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	0.000263	0.00144	CbGpPWpGaD
Dantrolene—CYP3A4—Tryptophan metabolism—MDM2—melanoma	0.000188	0.00103	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP17A1—melanoma	0.000166	0.000909	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP17A1—melanoma	0.000164	0.000896	CbGpPWpGaD
Dantrolene—CYP3A4—Biological oxidations—CYP1B1—melanoma	0.00014	0.000765	CbGpPWpGaD
Dantrolene—CYP3A4—Metapathway biotransformation—CYP1B1—melanoma	0.000138	0.000754	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ACER3—melanoma	9.31e-05	0.00051	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—UGT2B10—melanoma	8.51e-05	0.000466	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HS3ST5—melanoma	7.92e-05	0.000434	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PLCB4—melanoma	6e-05	0.000329	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIP4K2A—melanoma	5.64e-05	0.000309	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC6A11—melanoma	5.64e-05	0.000309	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—MTAP—melanoma	5.49e-05	0.000301	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PHGDH—melanoma	4.89e-05	0.000268	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—LUM—melanoma	4.89e-05	0.000268	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—HPSE—melanoma	4.8e-05	0.000263	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CUBN—melanoma	4.71e-05	0.000258	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SDHD—melanoma	4.55e-05	0.000249	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—BSG—melanoma	4.55e-05	0.000249	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CSPG4—melanoma	4.55e-05	0.000249	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GPAM—melanoma	4.4e-05	0.000241	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PLA2G6—melanoma	3.74e-05	0.000205	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—VCAN—melanoma	3.36e-05	0.000184	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP17A1—melanoma	2.84e-05	0.000155	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GNA11—melanoma	2.68e-05	0.000147	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—FASN—melanoma	2.62e-05	0.000144	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—SLC5A5—melanoma	2.58e-05	0.000141	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—GNAQ—melanoma	2.49e-05	0.000136	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CD44—melanoma	2.49e-05	0.000136	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—CYP1B1—melanoma	2.39e-05	0.000131	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ABCB1—melanoma	1.97e-05	0.000108	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PRKCA—melanoma	1.81e-05	9.91e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ERCC2—melanoma	1.8e-05	9.83e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CG—melanoma	1.42e-05	7.76e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PPARG—melanoma	1.37e-05	7.49e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CD—melanoma	1.25e-05	6.83e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—ALB—melanoma	1.23e-05	6.74e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CB—melanoma	1.09e-05	5.95e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTGS2—melanoma	1.08e-05	5.9e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PTEN—melanoma	9.39e-06	5.14e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—PIK3CA—melanoma	6.62e-06	3.63e-05	CbGpPWpGaD
Dantrolene—CYP3A4—Metabolism—AKT1—melanoma	5.41e-06	2.96e-05	CbGpPWpGaD
